Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several ways. Wh...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Phillips, W, Christadoss, P, Losen, M, Punga, A, Shigemoto, K, Verschuuren, J, Vincent, A
Natura:	Journal article
Lingua:	English
Pubblicazione:	Academic Press Inc. 2015

Documenti analoghi

Myasthenia gravis with MuSK antibodies
di: Farrugia, M, et al.
Pubblicazione: (2005)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.
di: Koneczny, I, et al.
Pubblicazione: (2014)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis
di: Koneczny, I, et al.
Pubblicazione: (2014)

Potential mechanisms in MuSK-myasthenia gravis
di: Koneczny, I
Pubblicazione: (2014)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
di: Shalini Bhaskar, et al.
Pubblicazione: (2022-01-01)

Infantile Onset Myasthenia Gravis with MuSK Antibodies
di: J Gordon Millichap
Pubblicazione: (2006-08-01)

The prevalence of MuSK antibody positive myasthenia gravis worldwide
di: Vincent, A, et al.
Pubblicazione: (2006)

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
di: McConville, J, et al.
Pubblicazione: (2004)

MuSK antibody-positive, seronegative myasthenia gravis in Korea.
di: Lee, J, et al.
Pubblicazione: (2006)

MuSK Antibody Positive Myasthenia Gravis Mimicking as Myositis
di: Nilesh Wagh, et al.
Pubblicazione: (2024-09-01)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
di: Carmelo Rodolico, et al.
Pubblicazione: (2020-07-01)

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
di: Jamie L. Lim, et al.
Pubblicazione: (2025-02-01)

MuSK-antibody-positive myasthenia gravis in a South Asian population.
di: Chang, T, et al.
Pubblicazione: (2009)

Anti-MuSK antibodies in a case of ocular myasthenia gravis.
di: Bennett, D, et al.
Pubblicazione: (2006)

Anti-MuSK antibody positive myasthenia gravis with childhood onset
di: Diana Epure, et al.
Pubblicazione: (2016-06-01)

Progress in rituximab for anti⁃MuSK antibody-related myasthenia gravis
di: Ting LI, et al.
Pubblicazione: (2020-01-01)

Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
di: Yung-Chuan Huang, et al.
Pubblicazione: (2008-07-01)

Anti-MuSK antibodies in seronegative myasthenia gravis: a cause of denervation
di: Newsom-Davis, J, et al.
Pubblicazione: (2001)

Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5.
di: Niks, E, et al.
Pubblicazione: (2006)

Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese.
di: Yeh, J, et al.
Pubblicazione: (2004)

Targeted treatment approaches and pathogenicity of antibody subclasses in MuSK-myasthenia gravis
di: Cao, M
Pubblicazione: (2021)

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
di: Fangyi Shi, et al.
Pubblicazione: (2024-11-01)

Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
di: Amber Eker, et al.
Pubblicazione: (2020-08-01)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
di: Zunwei Zhang, et al.
Pubblicazione: (2020-10-01)

Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
di: Shiraishi, H, et al.
Pubblicazione: (2005)

Myasthenia Crisis as First Presentation of MuSk Positive Myasthenia Gravis: A Case Report
di: Dipesh Chhetri, et al.
Pubblicazione: (2025-02-01)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
di: Lee, J, et al.
Pubblicazione: (2016)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
di: S. Lanfranconi, et al.
Pubblicazione: (2011-01-01)

MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets
di: Edyta Dziadkowiak, et al.
Pubblicazione: (2024-03-01)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
di: Christiane Schneider-Gold, et al.
Pubblicazione: (2017-10-01)

Quantitative EMG studies to assess facial muscle atrophy in MuSK antibody positive myasthenia gravis
di: Farrugia, M, et al.
Pubblicazione: (2007)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
di: Aigli G. Vakrakou, et al.
Pubblicazione: (2023-07-01)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
di: Vuslat Yilmaz, et al.
Pubblicazione: (2015-01-01)

Anti-MuSK antibody positive myasthenia gravis with Graves disease: one case report
di: Shan CAO, et al.
Pubblicazione: (2019-02-01)

MuSK Myasthenia Gravis in an HIV-infected Chinese old man successfully treated with pyridostigmine
di: Yirui Xie, et al.
Pubblicazione: (2020-09-01)

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
di: Deymeer, F, et al.
Pubblicazione: (2007)

MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
di: Farrugia, M, et al.
Pubblicazione: (2006)

Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.
di: Niks, E, et al.
Pubblicazione: (2008)

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression
di: Koneczny, I, et al.
Pubblicazione: (2024)

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
di: Hoch, W, et al.
Pubblicazione: (2001)